ART 4215
Alternative Names: ART-4215Latest Information Update: 11 Aug 2022
At a glance
- Originator Artios Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA polymerase theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer
- Phase I/II Solid tumours
Most Recent Events
- 11 Aug 2022 Phase-II clinical trials in Breast cancer in United Kingdom and USA (PO)
- 13 Sep 2021 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, In the elderly) in USA (PO) (NCT04991480)
- 12 Jan 2021 Preclinical trials in Cancer in United Kingdom (unspecified route) before January 2021